Pharmacokinetics and Pharmacodynamics of MPA in Stable Renal Transplant Patients
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by IRCCS Policlinico S. Matteo.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
IRCCS Policlinico S. Matteo
Information provided by:
IRCCS Policlinico S. Matteo
ClinicalTrials.gov Identifier:
NCT00780429
First received: October 24, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study of the pharmacokinetic and pharmacodynamic variability of mycophenolate mofetil in renal transplant patients already on long-term MMF treatment (at least 6 months post-transplant; at least 3 months in therapy).
Study hypothesis: to investigate whether long-term MMF therapy alters IMPDH biological activity and if there are any correlations with the risk of AR.
| Condition |
|---|
|
Kidney Transplantation |
| Study Type: | Observational |
| Official Title: | Evaluation of Pharmacokinetic and Pharmacodynamic Parameters in Renal Transplant Patients Receiving Mycophenolic Acid and Stable for at Least 3 Months |
Resource links provided by NLM:
MedlinePlus related topics:
Kidney Transplantation
Drug Information available for:
Mycophenolic acid
Mycophenolate sodium
Mycophenolate mofetil hydrochloride
Mycophenolate mofetil
U.S. FDA Resources
Further study details as provided by IRCCS Policlinico S. Matteo:
| Enrollment: | 54 |
| Study Start Date: | June 2006 |
| Groups/Cohorts |
|---|
|
1
MMF+cyclosporine
|
|
2
MMF+tacrolimus
|
|
3
MMF+sirolimus
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Male and female renal transplant patients
Criteria
Inclusion Criteria:
- Renal transplant recipients
- Age range: 18-70
- Patients taking MMF
- Able to understand and sign an informed consent
Exclusion Criteria:
- Active myelodepression
- Systemic infections or other that may affect MMF absorption
- Pregnancy/breastfeeding
- (History of) cancer
- Drug abuse, psychiatric conditions
- Already enrolled in other clinical trials or participation ended less than one month earlier
- Known sensitivity to polysorbate 80 or MMF
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Prof. Antonio Dal Canton, IRCCS Fondazione Policlinico San Matteo |
| ClinicalTrials.gov Identifier: | NCT00780429 History of Changes |
| Other Study ID Numbers: | 06/2006/REVO |
| Study First Received: | October 24, 2008 |
| Last Updated: | October 24, 2008 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by IRCCS Policlinico S. Matteo:
|
kidney transplant Mycophenolic acid Inosine monophosphate dehydrogenase |
Additional relevant MeSH terms:
|
Mycophenolic Acid Mycophenolate mofetil Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 22, 2013